No melt down as long as, as one poster wrote, Hopper doesn't screw up a great anns and let the market have its say for a change.
Converting the 0.8c oppies and maybe the shortfall placing should be the priority over another sp damaging cap raising sub 0.5c.
Of course that would take a bit of time to get absorbed by the market but if more great data are announced then bigger pockets will take care of that.
The big difference to the CDH17 trial is that all patients will be treated at MDA which makes recruitment and treatment more efficient and faster as these guys got the specialists and equipment already in place.
$8000 wasted or spent for a huge windfall in coming years, only time will tell.
GLTA
CHM Price at posting:
0.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)